Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced...
26 KB (2,188 words) - 05:17, 13 June 2024
disparities exist. She has also appeared in commercials for Prolia, a brand of denosumab used in the treatment of osteoporosis. Danner was married to producer...
33 KB (1,644 words) - 01:15, 3 July 2024
imperfecta to reduce the risk of broken bones. Combined teriparatide and denosumab increased BMD more than either agent alone and more than has been reported...
27 KB (2,054 words) - 06:31, 7 July 2024
rhabdomyolysis, tumor lysis syndrome, and medications such as bisphosphonates or denosumab. Diagnosis should generally be confirmed by determining the corrected...
19 KB (1,885 words) - 04:32, 21 March 2024
60-90% of patients who were treated for hypercalcemia of malignancy. Denosumab is a bone anti-resorptive agent that can be used to treat hypercalcemia...
34 KB (3,298 words) - 03:10, 27 March 2024
incident occurring in 2003. Osteonecrotic complications associated with denosumab, another antiresorptive drug from a different drug category, were soon...
46 KB (4,835 words) - 18:24, 9 December 2023
relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars. On November 1, 1986, a major fire broke out in a warehouse...
35 KB (2,761 words) - 03:18, 24 June 2024
it is no longer believed that they prevent progression of the disease. Denosumab has been found successful in reducing bone pain and decreasing tumor growth...
22 KB (2,346 words) - 01:36, 8 March 2024
metastases benefit from regular infusion of the bone-strengthening agents denosumab and the bisphosphonates; infusion every three months reduces the chance...
129 KB (14,628 words) - 14:31, 8 July 2024
tested in conjunction with calcium and vitamin D to encourage bone health. Denosumab, a monoclonal antibody treatment RANKl inhibitor that targets the osteocyte...
6 KB (673 words) - 19:26, 15 September 2022
February 2024 adalimumab-ryvk/Simlandi adalimumab/Humira March 2024 denosumab-bbdz/Jubbonti denosumab/Prolia March 2024 denosumab-bbdz/Wyost denosumab/Xgeva...
95 KB (6,480 words) - 22:51, 13 May 2024
baby's sex para-Dimethylaminobenzaldehyde, an organic chemical compound Denosumab, a drug for treating osteoporosis This disambiguation page lists articles...
322 bytes (70 words) - 21:26, 7 May 2018
10913. PMC 5342346. PMID 27486885. Chiu YG, Ritchlin CT (January 2017). "Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis". Expert Opinion...
147 KB (17,113 words) - 14:30, 9 July 2024
they shrink tumors. Other bone modifying agents like zoledronic acid and denosumab can reduce prostate cancer bone pain, even though they have little effect...
76 KB (8,857 words) - 11:18, 18 June 2024
PMID 24063695. S2CID 20163452. Gauthier K, Bai A, Perras C, et al. (2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:...
96 KB (9,392 words) - 18:47, 3 July 2024
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab...
52 KB (6,302 words) - 07:19, 27 April 2024
and bone-targeting chemotherapeutic agents such as bisphosphonates and denosumab. Orthopedic interventions such as internal fixation or spinal decompression...
25 KB (2,653 words) - 20:55, 22 May 2024
(esomeprazole) (only in Japan; marketed by AstraZeneca elsewhere) Pralia (denosumab) (only available in Japan; also sold there as Ranmark) Tarlige (mirogabalin)...
29 KB (2,326 words) - 13:59, 3 May 2024
osteoporosis such as estrogen replacement therapy, bisphosphonates or denosumab and for treatment hypercalciuria to reduce the risk for kidney stones...
21 KB (2,314 words) - 02:26, 12 July 2024
osteoclast-like cells. More recently, humanized monoclonal antibodies such as Denosumab targeting the RANK ligand have been employed in treatment of GCTOB in...
14 KB (1,604 words) - 22:41, 29 February 2024
one year, and the benefit was maintained after a second year of taking denosumab. In the other, one year of romosozumab followed by one year of alendronate...
12 KB (876 words) - 05:59, 15 July 2024
avenue of development for strategies targeting NF-κB inhibition. The drug denosumab acts to raise bone mineral density and reduce fracture rates in many patient...
89 KB (9,817 words) - 08:00, 10 June 2024
in 2023. Products under development include biosimilars of omalizumab, denosumab, golimumab, aflibercept, vedolizumab, and pembrolizumab. In November 2022...
11 KB (914 words) - 20:13, 22 June 2024
C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (February 2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:...
30 KB (3,429 words) - 02:49, 1 January 2024
Pharmaceutical, Hetero Drugs, Roche Influenza Oct-1999 Mon-20XX 91 Xgeva Denosumab 197,711 3.24% Amgen Osteoporosis Nov-2010 Mon-20XX 92 Evista Raloxifene...
29 KB (465 words) - 16:36, 9 July 2024
breast cancer, it increases the risk of blood clots and strokes. While denosumab is effective at preventing fractures in women, there is not clear evidence...
124 KB (13,913 words) - 18:29, 16 June 2024
(FDA approved 2008) Otezla (apremilast) Parsabiv (etelcalcetide) Prolia (denosumab) for postmenopausal osteoporosis Repatha (evolocumab) Riabni (rituximab-arrx)...
95 KB (7,725 words) - 21:13, 5 July 2024
needed] People with bone metastasis should receive bisphosphonates or denosumab to prevent skeletal related events (e.g. fractures, spinal cord compression...
130 KB (12,788 words) - 05:06, 8 July 2024
hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis. Denosumab SC RANKL inhibitor. Osteoporosis, including drug- and cancer-related osteoporosis...
52 KB (708 words) - 00:21, 11 April 2024